Custom ELISA Assay Development

ELISA Development Services

Build a custom ELISA assay when catalog kits or existing reagents are not enough.

Boster Bio supports antibody pair screening, assay optimization, matrix testing, and validation support for custom ELISA projects.

Custom targets or difficult biomarkers
Antibody pair screening
Assay optimization
Real sample matrix testing

Begin Inquiry

When Custom ELISA Development Makes Sense

Use this service when a catalog kit is not available, existing reagents need optimization, or assay performance must be confirmed in real biological samples.

No Suitable Kit

For difficult biomarkers, rare species, modified proteins, custom targets, or projects where an off-the-shelf ELISA kit cannot meet the research goal.

Existing Reagents Need Work

For projects with antibodies, standards, or a prototype assay that needs better sensitivity, lower background, or stronger standard curve performance.

Matrix Performance Is Unclear

For assays that work in buffer but need testing in serum, plasma, cell culture supernatant, lysate, tissue homogenate, or other biological samples.

What the Service Covers

Focused support for the key steps that determine whether an ELISA assay becomes usable, reproducible, and transferable.

Assay Development

Assay Format Design

Sandwich or competitive ELISA format selection based on target type, sample matrix, and assay goal.

Antibody Pair Screening

Capture and detection antibody evaluation for signal, background, compatibility, and native target recognition.

Condition Optimization

Coating, blocking, antibody dilution, incubation, detection, and standard curve setup.

Signal Troubleshooting

Support for weak signal, high background, poor dynamic range, and unstable standard curves.

Validation and Transfer Support

Matrix Performance Testing

Spike recovery, dilution linearity, and interference testing in relevant biological samples.

Analytical Evaluation

Precision, sensitivity, range, background, and assay robustness review based on project scope.

Protocol Finalization

Optimized working protocol, reagent recommendations, and practical assay setup guidance.

Documentation Support

Data summary and transfer-support documentation for RUO or customer-led IVD development workflows.

Ready to Discuss Your ELISA Assay Project?

Send your target, sample type, and current reagents. Boster Bio will review the project and recommend the next development step.

Request a Quote

Common ELISA Development Issues

Many ELISA projects fail not because the target is impossible, but because assay architecture, reagent pairing, or matrix testing was not resolved early enough.

Epitope and Antigen Mismatch

Antibody pairs that perform against recombinant antigen may fail when the native target has different folding, processing, or post-translational modification.

Matrix Interference and Background Noise

Assays optimized only in buffer can show high background, poor recovery, or nonlinear dilution when moved into serum, plasma, lysate, or tissue samples.

Weak Sensitivity or Narrow Range

Low-abundance targets often require careful tuning of antibody concentration, detection chemistry, standard curve range, and incubation conditions.

Transfer and Reproducibility Risk

Assays developed without reagent consistency, coating conditions, SOP compatibility, or documentation in mind may fail during transfer or repeat production.

Development Process

A checkpoint-based workflow helps identify weak assay designs before they move too far downstream.

Phase 1: Feasibility Review

Review target biology, species, sample matrix, expected concentration range, available reagents, and intended assay use.

Checkpoint: Confirm assay format, reagent needs, and development strategy.
Phase 2: Antibody Pair Screening

Evaluate capture and detection candidates for signal, background, epitope compatibility, and native target recognition.

Checkpoint: Select lead pair or recommend custom antibody or antigen development if needed.
Phase 3: Assay Optimization

Optimize coating concentration, blocking conditions, antibody dilution, incubation, detection, and standard curve setup.

Checkpoint: Advance when signal-to-noise, background, and preliminary range meet project targets.
Phase 4: Matrix Validation and Documentation

Evaluate recovery, dilution linearity, precision, sensitivity, range, and matrix interference in relevant sample types.

Checkpoint: Finalize optimized protocol, data summary, and transfer-support documentation as scoped.

Typical Deliverables

Deliverables depend on project scope, but most projects include practical assay data and documentation that support the next development decision.

Project Area	Typical Output
Feasibility	Target review, reagent assessment, assay format recommendation, and development plan.
Screening	Antibody pair screening data and lead pair recommendation.
Optimization	Optimized assay conditions, standard curve setup, and working protocol.
Validation	Matrix performance data, recovery, linearity, precision, sensitivity, and range evaluation as scoped.
Documentation	Data summary, optimized protocol, reagent recommendations, and transfer-support documentation when requested.

RUO and Customer-Led IVD Development Support

Boster Bio supports structured ELISA assay development with documentation, traceability, reagent control, and transfer considerations.

Development Support

Projects can be structured for research use or customer-led diagnostic development programs. U.S.-based execution supports direct communication, iterative troubleshooting, and flexible project review.

Important Note

Boster Bio does not claim FDA approval, GMP certification, or clinical certification for this service. If your project has specific regulatory or quality system requirements, include them in your inquiry.

FAQs

Common questions about custom ELISA assay development, antibody pair screening, matrix testing, and project requirements.

Q1. What should I provide for an ELISA development quote?

Please include the target name, species, sample matrix, expected assay format, available antibodies or standards, and intended use. If you already have preliminary data, failed assay results, or a current protocol, those details can help Boster Bio review the project more efficiently.

Q2. Can Boster Bio develop an ELISA if I do not have antibodies?

Yes. Depending on the target and project goal, the project can start with reagent review, antibody sourcing, or custom antibody and antigen development before moving into assay development.

Q3. Can you optimize an existing ELISA instead of developing one from scratch?

Yes. Boster Bio can help troubleshoot weak signal, high background, poor spike recovery, nonlinear dilution, narrow dynamic range, and matrix interference in an existing ELISA or prototype assay.

Q4. What sample matrices can be tested?

Common matrices include serum, plasma, cell culture supernatant, cell lysate, tissue homogenate, and other project-specific biological samples when feasible.

Q5. Do you support RUO and customer-led IVD development programs?

Yes. Boster Bio supports ELISA assay development for research use and customer-led diagnostic development programs with structured documentation, traceability, reagent control, and transfer considerations. Boster Bio does not claim FDA approval, GMP certification, or clinical certification for this service.

Q6. What are the typical deliverables of an ELISA development project?

Typical deliverables may include antibody pair screening data, optimized assay conditions, standard curve setup, matrix performance data, validation summary, optimized protocol, reagent recommendations, and transfer-support documentation depending on the agreed project scope.